After a weak first half, the drug and biotech sector has recovered in the past 2-3 months, with most large drugmakers signing drug pricing agreements with the Trump administration. After a cautious ...
Both Novo Nordisk NVO and Amgen AMGN are large-cap, innovation-driven healthcare leaders with global scale, strong balance ...